A Beginner’s Guide to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Care

A Beginner’s Guide to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Care is organized by Pharmacy Times Continuing Education (PTCE),Release date: September 7, 2022,Expiration date: September 7, 2023,Description:,Several vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are approved for the treatment of various tumor types. This activity will explore the role of VEGFR TKIs, with a focus on their use in renal cell, hepatocellular, and thyroid carcinomas. Despite their potency and selectivity, VEGFR TKIs are known to cause unique adverse effects (AEs) from those associated with chemotherapy and other targeted therapies. Pharmacists caring for patients with cancer must be familiar with the pharmacology and mechanism of action for these agents in order to recognize the potential for toxicity and manage drug interactions and AEs. Strategies for pharmacists to assist in the selection of therapy, provide adequate supportive care to patients, and manage AEs will be discussed. Animated videos within this activity will further reinforce the pathobiology of tumor angiogenesis, the pharmacology of TKIs targeting the VEGFR pathway, and the role of the pharmacist in managing toxicities.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Explore the pathobiology of tumor angiogenesis and the mechanism of action of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs),• Explain how differing potency, selectivity, and pharmacokinetics of VEGFR TKIs relate to efficacy in various tumor types,• Examine the shared and unique adverse drug reactions associated with FDA-approved VEGFR TKIs and treatment strategies to manage toxicities